Why 1000× stronger than Piracetam?

In dose-equivalent terms: 10 mg Noopept produces subjective effects similar to ~1200 mg Piracetam. The difference is higher affinity + more lipophilic molecule (better BBB passage), not strictly a different mechanism.

Sublingual gives faster Tmax (~15 min), higher bioavailability, bypasses first-pass hepatic metabolism. Most users go sublingual.

Is cycling necessary?

Recommended: 4-6 weeks on, 1-2 weeks off. Continuous NGF/BDNF stimulation carries tolerance and receptor downregulation risk.

How long can I use it continuously?

The Russian Rx protocol prescribes 56-day cycles followed by 2-4 weeks off. Continuous use beyond 3 months has not been formally studied – risk of receptor downregulation and NGF/BDNF tolerance.

PreclinicalResearch compound

Noopept

Name: Noopept
Creator: MolekulaX

Russian Rx racetam-like nootropic; small dose (10-30 mg), upregulates NGF/BDNF expression.

Available at

LIMITLESS-10% coupon: MOLEKULA

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

WHAT IS NOOPEPT?

Detailed overview

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a cyclic dipeptide derived from Piracetam, developed in Russia in the 1990s. Per-dose roughly 1000× more potent than Piracetam (10-30 mg/day vs. 4800 mg/day). Mechanism: AMPA + NMDA glutamatergic modulation plus NGF (nerve growth factor) and BDNF upregulation. OTC in Russia under the Noopept name; research chemical in EU/USA.

Mechanism

AMPA + NMDA + NGF/BDNF

Half-life

30-40 min (active metabolite)

Onset

15-30 min

Legal status

Russia OTC, EU/USA research

Safety

Side effects, stop signs, contraindications

Side effects · 6

Headache, typically with choline deficiency (mitigated by a choline source)
Irritability, agitation, especially at higher doses (>40 mg/day)
Insomnia, disturbed sleep if taken late in the day
Overstimulation, scattered focus, amplification of the signal-to-noise noise component
Mild dizziness or fatigue in some users
Tolerance and reduced effect with continuous, non-cycled use

Contraindications · 5

Pregnancy and breastfeeding (human safety data lacking)
Bipolar spectrum disorder: risk of agitation, irritability, manic switch
Severe renal or hepatic impairment (metabolism and clearance affected)
Concurrent alcohol use: increased sedation
Hypertension: blood pressure monitoring advised during use

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

Neurosci Behav Physiol. 2009;39(3):311-321.

Noopept (GVS-111) cognitive effects: randomized trial

Neznamov GG, Teleshova ES.

PMID: 19234797Open

Bulletin of experimental biology and medicine

Noopept stimulates the expression of NGF and BDNF in rat hippocampus.

Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al.

PMID: 19240853Open

Eksperimental'naia i klinicheskaia farmakologiia

The original novel nootropic and neuroprotective agent noopept.

Gudasheva TA, Voronina TA, Ostrovskaya RU, et al.

PMID: 12596521Open

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(10):44-50.

Noopept in the treatment of mild cognitive impairment in patients with stroke

Amelin AV, Iliukhina AIu, Shmonin AA.

PMID: 22500312Open

Eksp Klin Farmakol. 2008;71(4):8-13.

Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment

Neznamov GG, Teleshova ES.

PMID: 19008801Open

Have a question about Noopept?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: June 19, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.